Evaluation of Endoglin (CD105) expression in pediatric rhabdomyosarcoma.

BMC Cancer 2018 01 5;18(1):31. Epub 2018 Jan 5.

Department of Hematology/Oncology, Bambino Gesù Children's Hospital, IRCCS, Piazza di Sant'Onofrio, 4, 00165, Rome, Italy.

Background: The Intratumoral Microvessel Density (IMVD) is commonly used to quantify tumoral vascularization and is usually assessed by pan-endothelial markers, such as CD31. Endoglin (CD105) is a protein predominantly expressed in proliferating endothelium and the IMVD determined by this marker measures specifically the neovascularization. In this study, we investigated the CD105 expression in pediatric rhabdomyosarcoma and assessed the neovascularization by using the angiogenic ratio IMVD-CD105 to IMVD-CD31.

Methods: Paraffin-embedded archival tumor specimens were selected from 65 pediatric patients affected by rhabdomyosarcoma. The expression levels of CD105, CD31 and Vascular Endothelial Growth Factor (VEGF) were investigated in 30 cases (18 embryonal and 12 alveolar) available for this study. The IMVD-CD105 to IMVD-CD31 expression ratio was correlated with clinical and pathologic features of these patients.

Results: We found a specific expression of endoglin (CD105) in endothelial cells of all the rhabdomyosarcoma specimens analyzed. We observed a significant positive correlation between the IMVD individually measured by CD105 and CD31. The CD105/CD31 expression ratio was significantly higher in patients with lower survival and embryonal histology. Indeed, patients with a CD105/CD31 expression ratio < 1.3 had a significantly increased OS (88%, 95%CI, 60%-97%) compared to patients with higher values (40%, 95%CI, 12%-67%). We did not find any statistical correlation among VEGF and EFS, OS and CD105/CD31 expression ratio.

Conclusion: CD105 is expressed on endothelial cells of rhabdomyosarcoma and represent a useful tool to quantify neovascularization in this tumor. If confirmed by further studies, these results will indicate that CD105 is a potential target for combined therapies in rhabdomyosarcoma.

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-017-3947-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5755407PMC
January 2018
14 Reads

Publication Analysis

Top Keywords

endoglin cd105
12
cd105 cd31
8
pediatric rhabdomyosarcoma
8
cd105/cd31 expression
8
expression pediatric
8
expression ratio
8
cd105 expression
8
expression
7
cd105
6
endothelial growth
4
vegf investigated
4
factor vegf
4
growth factor
4
investigated cases
4
imvd-cd105 imvd-cd31
4
imvd-cd31 expression
4
ratio correlated
4
vascular endothelial
4
study imvd-cd105
4
embryonal alveolar
4

References

(Supplied by CrossRef)

JG Gurney et al.
1999

PH Sorensen et al.
J Clin Oncol 2002

HP McDowell et al.
Eur J Cancer 2010

JG de Castro et al.
Crit Rev Oncol Hematol 2006

JM Maris et al.
Pediatr Blood Cancer 2008

S Kumar et al.
Clin Cancer Res 2011

ST Keir et al.
Pediatr Blood Cancer 2012

F Navid et al.
Clin Cancer Res 2013

JL Glade Bender et al.
J Clin Oncol 2013

A Giatromanolaki et al.
Clin Cancer Res 1997

N Weidner et al.
Breast Cancer Res Treat 1995

Similar Publications